The new findings are the first to describe distributions and perturbations of low-density granulocyte and normal-density ...

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

Y-mAbs Therapeutics (YMAB) announced the publication of interim data from a Phase 2 clinical trial evaluating naxitamab with granulocyte-macrophage colony-stimulating factor, GM-CSF, in patients with ...

In metastatic triple-negative breast cancer, sacituzumab govitecan was effective and tolerable in the real-world setting.

LIfT's newly granted US patent (US 12,070,473 B2) secures robust protection for the treatment of cancer, including the use of ...

FORT LAUDERDALE, FL / ACCESS Newswire / March 10, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company ...

A heroic South Gloucestershire man gave a stranger a second chance at life with a stem cell donation. Jack Parsons wanted to pay it forward after his mum's life was saved - meaning she could meet her ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the launch of the aPAP ClearPath Dried Blood Spot (DBS) Test in the ...

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and ...

Published in Journal of the American Geriatrics Society, the study explored whether long-term use of non-steroidal ...

Coherus BioSciences (NASDAQ:CHRS – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Monday, March 10th. Analysts expect the company to announce ...

FORT LAUDERDALE, FL / ACCESS Newswire / March 10, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic area ...